Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William R Spreen

Showing results (1-10 of 44) with videos related to

Pageof 5
Sort By:
Current Opinion in HIV and AIDS|October 9, 2013
Long-acting injectable antiretrovirals for HIV treatment and preventionWilliam R Spreen, David A Margolis, John C Pottage
Antimicrobial Agents and Chemotherapy|October 23, 2024
Population pharmacokinetics of cabotegravir following intramuscular thigh injections in adults with and without HIVKelong Han, Ronald D D'Amico, William R Spreen, et al.
Clinical Pharmacology in Drug Development|July 11, 2025
Strategies to Manage Dosing Deviations and Interruptions of Cabotegravir Long-Acting Intramuscular InjectionsKelong Han, Ronald D D'Amico, William R Spreen, et al.
Pharmacogenomics|February 12, 2009
Genetic association studies to detect adverse drug reactions: abacavir hypersensitivity as an exampleArlene R Hughes, Cynthia H Brothers, Michael Mosteller, et al.
Antimicrobial Agents and Chemotherapy|February 7, 2022
Safety, Tolerability, Pharmacokinetics, and Acceptability of Oral and Long-Acting Cabotegravir in HIV-Negative Chinese MenKelong Han, Paul Wannamaker, Hongzhou Lu, et al.
Clinical Pharmacology in Drug Development|May 11, 2016
Effect of Cabotegravir on Cardiac Repolarization in Healthy SubjectsYu Lou, Ann M Buchanan, Shuguang Chen, et al.
Clinical Pharmacology in Drug Development|February 28, 2019
A Phase I Study to Evaluate the Pharmacokinetics and Safety of Cabotegravir in Adults With Severe Renal Impairment and Healthy Matched Control ParticipantsRidhi Parasrampuria, Susan L Ford, Yu Lou, et al.
Clinical Pharmacology in Drug Development|February 28, 2019
A Phase 1 Study to Evaluate the Pharmacokinetics and Safety of Cabotegravir in Patients With Hepatic Impairment and Healthy Matched ControlsJafar Sadik B Shaik, Susan L Ford, Yu Lou, et al.
The Journal of Antimicrobial Chemotherapy|May 4, 2020
Evaluation of the effect of UGT1A1 polymorphisms on the pharmacokinetics of oral and long-acting injectable cabotegravirParul Patel, Zhengyu Xue, Karen S King, et al.
Open Forum Infectious Diseases|March 30, 2022
Long-Term Efficacy, Safety, and Durability of Cabotegravir and Rilpivirine as 2-Drug Oral Maintenance Therapy After 6 Years of StudyKenneth C Sutton, Jerome De Vente, Roger Leblanc, et al.
Pageof 5

Showing results (1-10 of 44) with videos related to

Sort By:
Pageof 5
Current Opinion in HIV and AIDS|October 9, 2013
Long-acting injectable antiretrovirals for HIV treatment and preventionWilliam R Spreen, David A Margolis, John C Pottage
Antimicrobial Agents and Chemotherapy|October 23, 2024
Population pharmacokinetics of cabotegravir following intramuscular thigh injections in adults with and without HIVKelong Han, Ronald D D'Amico, William R Spreen, et al.
Clinical Pharmacology in Drug Development|July 11, 2025
Strategies to Manage Dosing Deviations and Interruptions of Cabotegravir Long-Acting Intramuscular InjectionsKelong Han, Ronald D D'Amico, William R Spreen, et al.
Pharmacogenomics|February 12, 2009
Genetic association studies to detect adverse drug reactions: abacavir hypersensitivity as an exampleArlene R Hughes, Cynthia H Brothers, Michael Mosteller, et al.
Antimicrobial Agents and Chemotherapy|February 7, 2022
Safety, Tolerability, Pharmacokinetics, and Acceptability of Oral and Long-Acting Cabotegravir in HIV-Negative Chinese MenKelong Han, Paul Wannamaker, Hongzhou Lu, et al.
Clinical Pharmacology in Drug Development|May 11, 2016
Effect of Cabotegravir on Cardiac Repolarization in Healthy SubjectsYu Lou, Ann M Buchanan, Shuguang Chen, et al.
Clinical Pharmacology in Drug Development|February 28, 2019
A Phase I Study to Evaluate the Pharmacokinetics and Safety of Cabotegravir in Adults With Severe Renal Impairment and Healthy Matched Control ParticipantsRidhi Parasrampuria, Susan L Ford, Yu Lou, et al.
Clinical Pharmacology in Drug Development|February 28, 2019
A Phase 1 Study to Evaluate the Pharmacokinetics and Safety of Cabotegravir in Patients With Hepatic Impairment and Healthy Matched ControlsJafar Sadik B Shaik, Susan L Ford, Yu Lou, et al.
The Journal of Antimicrobial Chemotherapy|May 4, 2020
Evaluation of the effect of UGT1A1 polymorphisms on the pharmacokinetics of oral and long-acting injectable cabotegravirParul Patel, Zhengyu Xue, Karen S King, et al.
Open Forum Infectious Diseases|March 30, 2022
Long-Term Efficacy, Safety, and Durability of Cabotegravir and Rilpivirine as 2-Drug Oral Maintenance Therapy After 6 Years of StudyKenneth C Sutton, Jerome De Vente, Roger Leblanc, et al.
Pageof 5